Literature DB >> 22999653

Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma.

Neville N Osborne1, Susana del Olmo-Aguado.   

Abstract

Loss of vision in glaucoma occurs because retinal ganglion cells (RGCs) die. RGCs have probably more mitochondria than any other neurone in the CNS. It is proposed that stress to mitochondria of individual RGCs is a major trigger of the disease and also provides an explanation why different RGCs die at different times. Pharmacological agents that can maintain mitochondrial functions, in particular to attenuate oxidative stress and to sustain energy production, might therefore provide a novel way of slowing down RGC death and help in the treatment of glaucoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999653     DOI: 10.1016/j.coph.2012.09.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  39 in total

1.  Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma.

Authors:  Dongwook Lee; Myoung Sup Shim; Keun-Young Kim; You Hyun Noh; Heemin Kim; Sang Yeop Kim; Robert N Weinreb; Won-Kyu Ju
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

Review 2.  Molecular imaging of retinal disease.

Authors:  Megan E Capozzi; Andrew Y Gordon; John S Penn; Ashwath Jayagopal
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-19       Impact factor: 2.671

Review 3.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

4.  Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation.

Authors:  Yvette C Wong; Erika L F Holzbaur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-07       Impact factor: 11.205

5.  Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma.

Authors:  K Namekata; A Kimura; K Kawamura; X Guo; C Harada; K Tanaka; T Harada
Journal:  Cell Death Differ       Date:  2013-07-12       Impact factor: 15.828

6.  Cumulative mtDNA damage and mutations contribute to the progressive loss of RGCs in a rat model of glaucoma.

Authors:  Ji-Hong Wu; Sheng-Hai Zhang; John M Nickerson; Feng-Juan Gao; Zhongmou Sun; Xin-Ya Chen; Shu-Jie Zhang; Feng Gao; Jun-Yi Chen; Yi Luo; Yan Wang; Xing-Huai Sun
Journal:  Neurobiol Dis       Date:  2014-12-03       Impact factor: 5.996

7.  Effects of a combinatorial treatment with gene and cell therapy on retinal ganglion cell survival and axonal outgrowth after optic nerve injury.

Authors:  Gabriel Nascimento-Dos-Santos; Leandro Coelho Teixeira-Pinheiro; Almir Jordão da Silva-Júnior; Luiza Rachel Pinheiro de Carvalho; Louise Alessandra Mesentier-Louro; William W Hauswirth; Rosalia Mendez-Otero; Marcelo Felippe Santiago; Hilda Petrs-Silva
Journal:  Gene Ther       Date:  2019-06-26       Impact factor: 5.250

8.  In Vivo Imaging of Retinal Oxidative Stress Using a Reactive Oxygen Species-Activated Fluorescent Probe.

Authors:  Megan C Prunty; Moe H Aung; Adam M Hanif; Rachael S Allen; Micah A Chrenek; Jeffrey H Boatright; Peter M Thule; Kousik Kundu; Niren Murthy; Machelle T Pardue
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

Review 9.  A case for neuroprotection in ophthalmology: developments in translational research.

Authors:  Andrew J Payne; Simon Kaja; Nelson R Sabates; Peter Koulen
Journal:  Mo Med       Date:  2013 Sep-Oct

10.  Mitochondrial haplogroup L1c2 is associated with increased disease severity in African American patients with primary open-angle glaucoma.

Authors:  Qi N Cui; Meera S Ramakrishnan; Harini V Gudiseva; David W Collins; Maxwell Pistilli; Roy Lee; Venkata M Chavali; Amanda Lehman; Victoria M Addis; Joan M O'Brien
Journal:  J Clin Exp Ophthalmol       Date:  2019-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.